SUMITOMO CHEMICAL COMPANY,LIMITED Q2 FY2027 earnings call

• Financial Performance Overview:

  • Core operating income reached JPY 14.45 billion for Q2, significantly exceeding forecasts and marking the second-highest first-half results on record.
  • Net income attributable to owners of the parent was JPY 8.29 billion, up JPY 4.32 billion YoY.
  • Sales revenue totaled JPY 117.28 billion, up JPY 7.74 billion YoY.
  • The debt-to-equity ratio improved significantly to 0.73x following Sumitomo Pharma's capital increase.

• Segment Operational Highlights:

  • Agro & Life Solutions: Crop protection demand outside Japan remains slow due to credit uncertainties and El Niño impacts in Latin America and India. Methionine margins improved despite high raw material costs.
  • ICT & Mobility Solutions: Semiconductor processing materials shipments increased due to strong AI-related demand. Super engineering plastics shipments rose, supported by Chinese economic stimulus measures.
  • Essential & Green Materials: Petrochemical results benefited from temporary inventory valuation gains and stable operations at Petro Rabigh, despite geopolitical tensions in the Middle East.
  • Sumitomo Pharma: Strong sales of ORGOVYX and GEMTESA drove shipment growth, though profits were impacted by the lack of one-time gains from previous asset sales.

• Balance Sheet and Cash Flow:

  • Total assets increased to JPY 3.6261 trillion, driven by working capital needs following the Chiba plant restart and higher naphtha prices.
  • Free cash flow was an outflow of JPY 1.83 billion, deteriorating compared to the prior year's inflow, primarily due to the absence of large proceeds from Sumitomo Pharma's Asian business sale.

• Agro & Life Solutions: Core operating income was JPY 2.08 billion (up JPY 960 million YoY). Revenue contribution is not explicitly stated as a percentage, but the segment contributed to overall growth despite slow recovery in overseas crop protection products. Feed additive margins improved.
• ICT & Mobility Solutions: Core operating income was JPY 3.19 billion (down JPY 120 million YoY). Display-related income declined due to semiconductor shortages and lower polarizing film prices, while semiconductor processing materials saw increased shipments and profit.
• Advanced Medical Solutions: Core operating income was a loss of JPY 370 million (down JPY 230 million YoY). Income dropped due to sales mix changes in active pharmaceutical ingredients and reduced margins at an affiliated company.
• Essential & Green Materials: Core operating income was JPY 6.21 billion (up JPY 8.07 billion YoY). Significant gains were driven by inventory valuation increases in Japan and Singapore and improved refining margins at Petro Rabigh.
• Sumitomo Pharma: Core operating income was JPY 4.36 billion (down JPY 5.38 billion YoY). Growth in ORGOVYX and GEMTESA shipments was offset by the absence of prior-year gains from the sale of the Asian business.

• Full-Year FY2026 Core Operating Income: Revised upward to JPY 27.0 billion (from JPY 25.0 billion previously), reflecting a JPY 5.5 billion increase. This is expected to be a record high.
• Full-Year FY2026 Net Income Attributable to Owners of the Parent: Revised upward to JPY 9.0 billion (from JPY 7.0 billion previously), representing a JPY 2.0 billion increase.
• Dividend Guidance: Year-end dividend revised upward to JPY 9 per share (up JPY 1), making the full-year projected dividend JPY 17 per share (up JPY 1).
• Segment Forecasts:
  • ICT & Mobility Solutions: Core income revised up to JPY 6.0 billion (from JPY 5.5 billion) due to semiconductor material shipments.
  • Essential & Green Materials: Core income revised up to JPY 7.5 billion (from JPY 2.0 billion) due to Petro Rabigh improvements and inventory gains.
  • Sumitomo Pharma: Core income revised up to JPY 10.8 billion (from JPY 9.4 billion) due to strong GEMTESA sales.
  • Agro & Life Solutions: Forecast unchanged due to delayed recovery in overseas crop protection markets.
• Key Assumptions: Exchange rate assumed at JPY 157 for the full year (JPY 150 for H2); Naphtha price assumed at JPY 99,000 per kiloliter for the full year.

• Geopolitical Instability: Ongoing tensions in the Middle East create uncertainty for supply chains and operations, particularly impacting Petro Rabigh and feed additive logistics.
• Agricultural Market Delays: Recovery of crop protection demand in Central/South America and India is delayed due to farmer credit issues and El Niño weather patterns.
• Raw Material Volatility: High naphtha prices continue to pressure petrochemical margins, although management expects some recovery in the second half.
• Foreign Exchange Exposure: A weaker yen against the dollar has increased finance losses, including significant losses from foreign currency transactions.
• Operational Uncertainties: Specific risks related to Singapore operations (force majeure status) and potential non-recurring items are factored into the 'Others' segment forecast as a buffer.

Q: Morgan Stanley asked about the underperformance in Agro & Life Solutions in Q2 versus forecast, specifically regarding overseas crop protection delays and methionine pricing.

A: Yamauchi explained that demand recovery in Latin America and India is delayed due to farmer credit uncertainties and El Niño impacts. While methionine prices were high in H1 due to supply confusion, they are stabilizing. Management anticipates a shift in shipments to H2 and better methionine performance than initially forecasted, leading to an upward revision for H2, despite a downward adjustment for overall crop protection chemicals compared to May forecasts.

Q: Mizuho Securities inquired about the ICT & Mobility Solutions segment, noting that the H2 core income forecast (JPY 28.1 billion) is nearly double H1 (JPY 13.9 billion) and asking if this is driven by semiconductors.

A: Yamauchi confirmed that semiconductor-related products, particularly front-end resist and chemicals, are strongly performing and will grow further in H2. He noted that while display segments typically decline in H2 due to seasonality, the strong semiconductor growth mitigates this difference. Super engineering plastics also remain strong due to Chinese economic stimulus boosting electronic component shipments.

Q: SMBC Nikko Securities questioned the Essential & Green Materials forecast, noting a large upward revision for H1 and asking about assumptions for Petro Rabigh and Singapore operations given geopolitical disruptions.

A: Yamauchi stated that H1 gains were largely due to inventory valuation gains and stabilization in the Middle East. For H2, refining margins are advancing steadily, but management is incorporating risk factors for the fourth quarter. Regarding Singapore, operations remain constrained by force majeure declarations and high naphtha prices, with no significant change from Q1 levels. Management excluded certain business sales gains from the core forecast to maintain conservatism.

Q: Daiwa Securities asked about the negative 'Other' adjusted area in the H2 forecast (-JPY 3.0 billion) and whether it serves as a risk buffer.

A: Yamauchi clarified that approximately JPY 1.0 billion is incorporated for specific risks, primarily the uncertain Middle East situation. Additionally, while naphtha price assumptions suggest inventory valuation recovery, areas with low visibility are included as general risk factors. Non-recurring items are also expected to be more prominent in H2, similar to the previous fiscal year, reflecting restructuring and other expenses.

Q: Nomura Securities asked about the rationale behind the increased dividend guidance (JPY 17 total vs. JPY 16 previously) given uncertainties in H2 and next year's outlook.

A: Yamauchi explained that the decision was based on a comprehensive look at current performance and future outlooks. While H1 was strong and H2 has uncertainties, the company aims to maintain the record-high dividend level if future outlooks brighten. However, they emphasized that dividend decisions will be re-evaluated based on the clarity of the next fiscal year's prospects.